Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | NT5E | P21589 | 1/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.66 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.64 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL314542 | 0.82 | ADORA3 (0.76) | LMNANT5EHIF1AADORA2AADORA2B | |
| SCHEMBL7932653 | 0.82 | ADORA3 (0.76) | LMNANT5EHIF1AADORA2AADORA2B | |
| SCHEMBL278293 | 0.82 | ADORA3 (0.76) | LMNANT5EHIF1AADORA2AADORA2B | |
| SCHEMBL10040218 | 0.82 | ADORA3 (0.76) | LMNANT5EHIF1AADORA2AADORA2B | |
| SCHEMBL6725190 | 0.82 | ADORA3 (0.76) | LMNANT5EHIF1AADORA2AADORA2B | |
| SCHEMBL24146779 | 0.82 | ADORA3 (0.76) | LMNANT5EHIF1AADORA2AADORA2B | |
| SCHEMBL13461111 | 0.82 | ADORA3 (0.76) | LMNANT5EHIF1AADORA2AADORA2B | |
| SCHEMBL14131245 | 0.82 | ADORA3 (0.76) | LMNANT5EHIF1AADORA2AADORA2B | |
| SCHEMBL259446 | 0.82 | ADORA3 (0.76) | LMNANT5EHIF1AADORA2AADORA2B | |
| SCHEMBL25756712 | 0.82 | ADORA3 (0.76) | LMNANT5EHIF1AADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140213541-A1 | AGONISTS OF A2A ADENOSINE RECEPTORS FOR TREATING RECURRENT TUMOR GROWTH | ADENOSINE THERAPEUTICS, LLC (US) | 2014-07-31 | — | — | US | disclosed |
| US-8551972-B2 | Agonists of A2A adenosine receptors for treating recurrent tumor growth | ADENOSINE THERAPEUTICS, LLC (US) | 2013-10-08 | — | — | US | disclosed |
| EP-2266994-B1 | 2-propynyl adenosine analgos with modified 5'-ribose groups having A2A agonist activity | Univ Virginia Patent Found (US) | 2013-04-03 | — | — | EP | disclosed |
| EP-1778712-B1 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | Univ Virginia Patent Found (US) | 2013-01-30 | — | — | EP | disclosed |
| US-8293720-B2 | Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists | DOGWOOD PHARMACEUTICALS, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8252767-B2 | Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists | DOGWOOD PHARMACEUTICALS, INC. (US) | 2012-08-28 | — | — | US | disclosed |
| US-8222228-B2 | Substituted aryl piperidinylalkynyladenosines as A2AR agonists | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2012-07-17 | — | — | US | disclosed |
| US-8188063-B2 | A2A receptor agonists for the central nervous system; antiinflammatory agents; 2,7-disubstituted-5-amino-pyrazolo[4,3-e]-[1,2,4]-triazolo[1,5-c]pyrimidines, mefloquine, 8-(3-chlorostyryl)caffeine, 3,7,8-trisubstituted-1-propargyl-xanthines; 2,5-disubstituted-7-amino-[1,2,4]triazolo[1,5-a][1,3,5]triazines | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-29 | — | — | US | disclosed |
| US-8178509-B2 | Method to treat sickle cell disease | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-15 | — | — | US | disclosed |
| US-8158604-B2 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-04-17 | — | — | US | disclosed |
| US-20060040889-A1 | 2-polycyclic propynyl adenosine analogs having A2A agonist activity | ADENOSINE THERAPEUTICS, L.L.C | 2006-02-23 | — | — | US | disclosed |
| US-20060040888-A1 | 2-propynyl adenosine analogs with modifed 5'-ribose groups having A2A agonist activity | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-02-23 | — | — | US | disclosed |
| WO-2006015357-A2 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20050261236-A1 | Agonists of A2A adenosine receptors for treatment of diabetic nephropathy | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-11-24 | — | — | US | disclosed |
| WO-2005107463-A1 | AGONISTS OF A2A ADENOSINE RECEPTORS FOR TREATMENT OF DIABETIC NEPHROPATHY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2005-11-17 | — | — | WO | disclosed |
| US-20050182018-A1 | Method to reduce inflammatory response in transplanted tissue | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-08-18 | — | — | US | disclosed |
| EP-1496911-A1 | USE OF A2A ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-1434782-A2 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | University of Virginia Patent Foundation (US) | 2004-07-07 | — | — | EP | disclosed |
| WO-2003086408-A1 | USE OF A2A ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003029264-A2 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213541-A1 | AGONISTS OF A2A ADENOSINE RECEPTORS FOR TREATING RECURRENT TUMOR GROWTH | ADORA2A, ADORA3, ADORA1 | LMNA 4253/4885NT5E 79/4885HIF1A 1157/4885 |
| US-20050261236-A1 | Agonists of A2A adenosine receptors for treatment of diabetic nephropathy | ADORA2A, ADORA3, PDE4A | LMNA 3193/4885NT5E 43/4885HIF1A 1423/4885 |
| US-20050182018-A1 | Method to reduce inflammatory response in transplanted tissue | ADORA2A, PDE4A, PDE4B | LMNA 3366/4885NT5E 63/4885HIF1A 834/4885 |
| US-20060040889-A1 | 2-polycyclic propynyl adenosine analogs having A2A agonist activity | ADORA2A, ADORA3, ADORA1 | LMNA 1401/4885NT5E 92/4885HIF1A 1878/4885 |
| US-20060040888-A1 | 2-propynyl adenosine analogs with modifed 5'-ribose groups having A2A agonist activity | ADORA2A, ADORA3, ADORA1 | LMNA 1458/4885NT5E 43/4885HIF1A 2528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.